Medeon Biodesign

Medeon Biodesign

6499 · TWO · Healthcare / Medical Instruments & Supplies

73.00TWD+0.60 (+0.83%)

Price History

Full chart

Market Stats

Previous Close72.40
Open74.00
Day Range72.70 – 74.20
52-Week Range55.80 – 134.00
Volume189.79K
Market Cap7.74B
P/E (TTM)0.00
Forward P/E0.00
EPS-5.92
Dividend Yield0.00%
Beta0.63
50-Day Avg68.07
200-Day Avg81.81

About

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEODr. Yue-Teh Jang Ph.D.
  • Employees0
  • Headquarters116, HouGang Street, Taipei, Taiwan, 11170, Taiwan
  • Websitehttps://www.medeonbiodesign.com

Leadership

  • Dr. Yue-Teh Jang Ph.D.Chairman of the Board & GM
  • Dr. Jenny ChenVP of Finance & Business Analysis, Head of Corporate Governance and CFO
  • Ms. Tori LinSenior Manager of Finance & Business Analysis and Accounting Officer
  • Ms. Greta ChangExecutive Vice President
  • Mr. Albert WengVP of Products Development

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue164.77M673.53M453.76M653.90M68.96M298.32M196.26M292.81M419.43M
Growth (%)-+308.78%-32.63%+44.11%-89.45%+332.61%-34.21%+49.19%+43.24%
Cost of Revenue118.96M192.41M267.52M298.48M40.33M111.50M181.89M209.39M360.60M
Gross Profit45.80M481.12M186.24M355.42M28.63M186.81M14.38M83.41M58.83M
Gross Margin27.80%71.43%41.04%54.35%41.52%62.62%7.33%28.49%14.03%
Operating Expense319.31M306.56M442.94M452.38M524.22M674.65M853.37M955.62M781.27M
Operating Income-273.51M174.56M-256.70M-96.97M-495.59M-487.84M-838.99M-872.20M-722.45M
Operating Margin-166.00%25.92%-56.57%-14.83%-718.69%-163.53%-427.48%-297.87%-172.25%
EBITDA-230.10M266.11M-172.08M-26.10M-453.87M-370.10M-1.13B-754.42M-608.65M
EBITDA Margin-139.65%39.51%-37.92%-3.99%-658.19%-124.06%-574.93%-257.65%-145.11%
Net Income-247.52M256.60M-261.99M-192.74M2.08B-433.76M-1.20B-805.51M-668.06M
Net Income Margin-150.22%38.10%-57.74%-29.47%3013.75%-145.40%-613.78%-275.10%-159.28%
R&D216.26M197.45M300.95M312.52M415.87M521.62M667.46M751.87M587.19M
R&D as % of Total Revenue131.25%29.32%66.32%47.79%603.09%174.85%340.08%256.78%140.00%
Interest Expense09.00K2.74M3.28M1.03M5.21M6.64M5.55M3.68M
Interest Expense % of Total Revenue0.00%0.00%0.60%0.50%1.49%1.75%3.39%1.90%0.88%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.64B1.95B2.52B3.31B4.36B4.04B2.75B1.88B1.78B
Total Liabilities105.41M148.89M268.18M666.83M176.00M376.48M375.65M341.84M243.03M
Total Equity1.34B1.64B2.00B2.05B4.13B3.60B2.32B1.52B1.48B
Cash285.27M328.11M472.06M1.13B735.32M483.90M1.24B513.37M520.79M

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-310.76M322.05M-241.99M-151.27M-293.38M-461.34M-755.08M-832.66M-629.14M
Investing Cash Flow-27.03M-314.64M-320.66M245.63M-90.64M263.44M---
Financing Cash Flow78.76M30.96M711.25M565.84M-3.90M-101.16M---
Capital Expenditure148.56M51.14M48.90M20.16M8.32M140.57M55.81M74.77M16.88M
Free Cash Flow-459.90M267.58M-293.32M-172.43M-302.39M-602.06M-810.89M-907.44M-646.01M
Dividends Paid--73.03M73.03M73.03M73.03M43.82M--
FCF to OCF147.99%83.09%121.21%113.98%103.07%130.50%107.39%108.98%102.68%
Dividend Paid to FCF---24.90%-42.35%-24.15%-12.13%-5.40%--

Earnings

Report DateMay 8, 2018Aug 6, 2018Nov 12, 2018Mar 20, 2019May 11, 2019Feb 28, 2020Nov 5, 2020Feb 24, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 24, 2022May 6, 2022Aug 5, 2022Nov 4, 2022May 7, 2025Aug 7, 2025Nov 6, 2025Mar 9, 2026May 11, 2026Aug 13, 2026
EPS Estimate0.130.79--1.25-1.03--0.550.26-25.19-0.76-0.87-0.48-1.61-2.29-1.69-1.75-1.96-1.86-1.80
EPS Actual4.68-0.32-0.84-0.74-0.82-1.14-0.69-0.15-0.83-1.52-1.94-1.220.72-2.09-1.35-1.93-1.93-1.90-1.48-1.26-1.28
Surprise3500.00%-140.51%-40.80%20.39%--25.45%-157.69%--106.03%-155.26%--17.24%-335.42%16.15%15.72%-14.20%-8.57%24.49%32.26%28.89%
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap7.74B
Enterprise Value6.30B
Trailing P/E0.00
Forward P/E0.00
Price / Sales18.07
Price / Book5.78
EPS-5.92
Book Value12.69
Revenue (TTM)428.06M
Gross Profit (TTM)56.08M
EBITDA-566.81M
Profit Margin-130.48%
Operating Margin-131.56%
Return on Equity-51.16%
Return on Assets-26.09%
Shares Outstanding96.94M
Shares Float55.54M
Beta0.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
0.50Aug 23, 2023
20221×
0.94Aug 22, 2022

Stock Splits

  • Aug 23, 20231049.9929:1000
  • Aug 22, 20221200:1000
  • Aug 23, 20211100:1000
  • Jul 5, 20191099.917:1000